Alprostadil in Maculopathy Study (AIMS)

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Macular Degeneration

Interventions

DRUG

Alprostadil (prostaglandin E1)

Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.

OTHER

Placebo

Placebo/d i.v. for 15 days

Trial Locations (6)

Berlin

Bochum

Dortmund

Karlsruhe

München

Münster